Immunodiagnostic launches first product in fertility portfolio

Specialty clinical laboratory diagnostic solutions company Immunodiagnostic Systems Holdings announced the launch of the IDS-iSYS 17-OH Progesterone assay in the European market - the first product released as part of its upcoming steroid hormones fertility portfolio.

The AIM-traded firm said the assay measures a patient’s 17-OH Progesterone level, and offers clinicians a non-invasive way to diagnose disorders of the adrenal gland or ovaries such as congenital adrenal hyperplasia or polycystic ovary syndrome.

Women with PCOS have higher than normal levels of 17-OH Progesterone, the company said, which can be a cause of infertility.

“As the only fully automated solution on the market, the IDS-iSYS 17-OH Progesterone assay allows laboratories to benefit from reduced time to first result for measurement of patient samples,” Immunodiagnostic’s board said in a statement.

It said the global market size of 17-OH Progesterone testing is estimated to be between £7m and £10m.